Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Receivables (2022 - 2026)

TriSalus Life Sciences has reported Receivables over the past 5 years, most recently at $5.2 million for Q1 2026.

  • For Q1 2026, Receivables fell 5.18% year-over-year to $5.2 million; the TTM value through Mar 2026 reached $5.2 million, down 5.18%, while the annual FY2025 figure was $6.6 million, 28.59% up from the prior year.
  • Receivables for Q1 2026 was $5.2 million at TriSalus Life Sciences, down from $6.6 million in the prior quarter.
  • Over five years, Receivables peaked at $6.6 million in Q4 2025 and troughed at $1.6 million in Q4 2022.
  • A 5-year average of $4.6 million and a median of $5.0 million in 2024 define the central range for Receivables.
  • Biggest five-year swings in Receivables: surged 131.21% in 2023 and later decreased 5.18% in 2026.
  • Year by year, Receivables stood at $1.6 million in 2022, then surged by 131.21% to $3.6 million in 2023, then surged by 41.67% to $5.1 million in 2024, then rose by 28.59% to $6.6 million in 2025, then dropped by 20.48% to $5.2 million in 2026.
  • Business Quant data shows Receivables for TLSI at $5.2 million in Q1 2026, $6.6 million in Q4 2025, and $5.0 million in Q3 2025.